← Back to feedRead original →
VERIFIEDET Stocks·negative
Zydus Lifesciences shares drop 3% after Q1 earnings. Here's why Nuvama upgraded rating, hiked target
AI Summary
- ·Zydus Lifesciences reported a 36% year-on-year drop in net profit for Q1.
- ·Operational revenue increased by nearly 22%, while expenses surged over 41%.
- ·Nuvama upgraded the stock to 'Buy' and raised its price target.